Okamura, Akihiko
Watanabe, Masayuki http://orcid.org/0000-0003-0298-1597
Okui, Jun
Matsuda, Satoru
Takemura, Ryo
Kawakubo, Hirofumi
Kakeji, Yoshihiro
Kono, Koji
Kitagawa, Yuko
Takeuchi, Hiroya
Article History
Received: 28 July 2023
Accepted: 3 November 2023
First Online: 24 November 2023
Declarations
:
: The Ethics Committee of all participating esophageal centers approved this study. Written informed consent was waived because all subjects had completed treatment, the study only used anonymized patient information, and the study was designed as a retrospective observational study with no interventions or invasive procedures. Following the Ethics Committee’s approval of this study, a document was made public to provide information about the research’s goals as well as the option to opt out.
: All authors have no conflicts of interest and source of funding regarding this research. Yuko Kitagawa; Relevant Financial Activities Outside the Submitted Work: CHUGAI PHARMACEUTICAL CO., LTD. TAIHO PHARMACEUTICAL CO., LTD Yakult Honsha Co. Ltd. ASAHI KASEI PHARMA CORPORATION Otsuka Pharmaceutical Co., Ltd. Takeda Pharmaceutical Co., Ltd. ONO PHARMACEUTICAL CO., LTD. TSUMURA & CO. Kyouwa Hakkou Kirin Co., Ltd. EA Pharma Co., Ltd. MEDICON INC. KAKEN PHARMACEUTICAL CO. LTD. Eisai Co., Ltd. Otsuka Pharmaceutical Factory Inc. TEIJIN PHARMA LIMITED. NIHON PHARMACEUTICAL CO., LTD. Nippon Covidien Inc. SHIONOGI & CO., LTD. Ethicon, Inc. Olympus Corporation Bristol-Myers Squibb K.K. AstraZeneca K.K. MSD K.K. Smith & Nephew KK ASKA Pharmaceutical Co., Ltd. MIYARISAN PHARMACEUTICAL CO. LTD.